Peptide Receptor Radionuclide Therapy in Patients with Inoperable Meningiomas: Our Experience and Review of the Literature

Peptide receptor imaging in neuroendocrine tumors: comparison between diagnostic scintigraphy and post-therapy whole-body scan

(2013) Fabio Minutoli et al.   ANNALS OF NUCLEAR MEDICINE

mTORC1 Inhibitors Suppress Meningioma Growth in Mouse Models

(2013) D. Pachow et al.   CLINICAL CANCER RESEARCH

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

(2013) John J. Zaknun et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Integration of functional neuroimaging in CyberKnife radiosurgery: feasibility and dosimetric results

(2013) Alfredo Conti et al.   Neurosurgical Focus

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

(2012) Emil Lou et al.   JOURNAL OF NEURO-ONCOLOGY

Atypical and anaplastic meningiomas treated with bevacizumab

(2012) Lakshmi Nayak et al.   JOURNAL OF NEURO-ONCOLOGY

First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment

(2012) S. Baldari et al.   Pituitary

Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma

(2012) Michael C Kreissl et al.   Radiation Oncology

Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy

(2012) Maria Larsson et al.   EJNMMI Research

Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes

(2011) A. Durand et al.   CLINICAL NEUROPATHOLOGY

Meningioma: review of the literature with emphasis on the approach to radiotherapy

(2011) Gustavo Nader Marta et al.   Expert Review of Anticancer Therapy

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

(2011) Anna Imhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series

(2011) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma

(2011) Marc C. Chamberlain   JOURNAL OF NEURO-ONCOLOGY

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma

(2011) D. R. Johnson et al.   NEURO-ONCOLOGY

Successful radiopeptide targeting of metastatic anaplastic meningioma: Case report

(2011) Amir Sabet et al.   Radiation Oncology

Bevacizumab-induced regression of anaplastic meningioma

(2010) M. J. A. Puchner et al.   ANNALS OF ONCOLOGY

111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging

(2010) Emilio Bombardieri et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors

(2010) Dik J. Kwekkeboom et al.   SEMINARS IN NUCLEAR MEDICINE

Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma

(2009) Mirco Bartolomei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs

(2009) Dik J. Kwekkeboom et al.   NEUROENDOCRINOLOGY

Interferon-α for recurrent World Health Organization grade 1 intracranial meningiomas

(2008) Marc C. Chamberlain et al.   CANCER

Safety and Efficacy of Radionuclide Therapy with High-Activity In-111 Pentetreotide in Patients with Progressive Neuroendocrine Tumors

(2008) Ebrahim S. Delpassand et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

(2008) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING